Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
RLMD - Relmada Therapeutics, Inc.
Market Cap 77.35M P/E - EPS this Y 22.00% Ern Qtrly Grth -
Income -86.76M Forward P/E -1.00 EPS next Y 13.70% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.62 EPS next 5Y - 52W High Chg -93.00%
Recommedations 2.00 Quick Ratio 7.39 Shares Outstanding 30.17M 52W Low Chg 42.00%
Insider Own 8.04% ROA -59.13% Shares Float 27.53M Beta 0.51
Inst Own 46.17% ROE -100.41% Shares Shorted/Prior 1.18M/1.29M Price 2.57
Gross Margin - Profit Margin - Avg. Volume 187,843 Target Price 12.50
Oper. Margin - Earnings Date Nov 6 Volume 89,237 Change 0.39%
Healthcare | Biotechnology | United States
About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc. News
12/09/24 Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
12/05/24 Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
12/04/24 Sector Update: Health Care Stocks Edge Lower Late Afternoon
12/04/24 Top Midday Decliners
12/04/24 Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
12/02/24 US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks
11/19/24 Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/14/24 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
11/10/24 Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024
11/08/24 Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
11/07/24 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/04/24 Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
10/22/24 3 US Penny Stocks To Monitor In October 2024
09/13/24 Insider Spends US$395k Buying More Shares In Relmada Therapeutics
09/12/24 Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)
09/12/24 Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares
08/21/24 Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?
08/12/24 Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
08/08/24 Q2 2024 Relmada Therapeutics Inc Earnings Call
08/07/24 Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Jan 29 Buy 3.87 100,000 387,000 244,024 01/31/24
Shenouda Maged Chief Financial Offi.. Chief Financial Officer Jan 29 Buy 3.87 32,675 126,452 34,903 01/31/24
Ence Chuck CA and CO CA and CO Jan 29 Buy 3.86 38,970 150,424 38,970 01/31/24
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Dec 08 Buy 2.096 55,250 115,804 144,024 12/12/22
Kelly Paul Edward Director Director Apr 04 Option 3.24 10,000 32,400 197,295 04/05/22
Kelly Paul Edward Director Director Apr 04 Sell 30.04 10,000 300,400 187,295 04/05/22
Shenouda Maged CFO CFO Mar 10 Option 3.24 10,000 32,400 12,228 03/10/21
Shenouda Maged CFO CFO Mar 10 Sell 35.39 10,000 353,900 2,228 03/10/21
TRAVERSA SERGIO CEO CEO Feb 16 Option 3.24 1,446 4,685 90,220 02/16/21
TRAVERSA SERGIO CEO CEO Feb 16 Sell 35.43 1,446 51,232 88,774 02/16/21
TRAVERSA SERGIO CEO CEO Feb 10 Option 3.24 11,206 36,307 99,980 02/10/21
TRAVERSA SERGIO CEO CEO Feb 10 Sell 35.17 11,206 394,115 88,774 02/10/21
Kelly Paul Edward Director Director Feb 10 Option 3.24 3,569 11,564 165,864 02/10/21
Kelly Paul Edward Director Director Feb 10 Sell 35.16 3,569 125,486 162,295 02/10/21
Shenouda Maged CFO CFO Feb 10 Sell 35.16 11,372 399,840 2,228 02/10/21
Shenouda Maged CFO CFO Feb 10 Option 3.24 11,372 36,845 13,600 02/10/21
TRAVERSA SERGIO CEO CEO Feb 04 Option 3.24 3,278 10,621 92,052 02/04/21
TRAVERSA SERGIO CEO CEO Feb 04 Sell 35.04 3,278 114,861 88,874 02/04/21
Shenouda Maged CFO CFO Feb 04 Option 3.24 3,200 10,368 5,428 02/04/21
Shenouda Maged CFO CFO Feb 04 Sell 35.02 3,200 112,064 2,228 02/04/21
TRAVERSA SERGIO CEO CEO Jan 29 Option 3.24 10,000 32,400 85,493 01/29/21
TRAVERSA SERGIO CEO CEO Jan 29 Sell 32.69 10,000 326,900 75,493 01/29/21
Kelly Paul Edward Director Director Jan 29 Option 3.24 5,000 16,200 152,295 01/29/21
Kelly Paul Edward Director Director Jan 29 Sell 32.66 5,000 163,300 147,295 01/29/21
Kelly Paul Edward Director Director Jan 26 Option 3.24 4,085 13,235 151,380 01/26/21
Kelly Paul Edward Director Director Jan 26 Sell 912.4 4,085 3,727,154 147,295 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Option 3.24 4,070 13,187 79,563 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Sell 35.51 4,070 144,526 75,493 01/26/21
Shenouda Maged CFO CFO Jan 26 Option 324 4,000 1,296,000 6,228 01/26/21
Shenouda Maged CFO CFO Jan 26 Sell 35.5 4,000 142,000 2,228 01/26/21
CASAMENTO CHARLES J Director Director Dec 02 Sell 35.74 3,000 107,220 24,950 12/02/20